Literature DB >> 7868896

Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.

R I Smith1, M J Coloma, S L Morrison.   

Abstract

The 18-amino acid carboxyl-terminal tailpiece from IgM (mutp) has now been added to the carboxyl-termini of IgG1, IgG2, IgG3, and IgG4 constant regions to produce recombinant IgM-like IgGs. Polymeric IgGs obtained by this approach possess up to six Fcs and 12 antigen-combining sites, greatly increasing the avidity of their interactions with other molecules. Not surprisingly, the C activity of normally active IgG1 and IgG3 and somewhat less active IgG2 Abs is shown to be dramatically enhanced upon polymerization. The multiple Fcs present in a single molecule apparently allow for more efficient interactions with the multiple C1q heads present in C1, the first component of the classical C cascade. An unexpected result however, is that IgG4, normally devoid of C activity, when polymerized in the same fashion directs C-mediated lysis of target cells almost as effectively as the other polymers. Interestingly though, IgG4mutp does not deplete C activity in a standard consumption assay using soluble Ag. The other gamma mutp isotypes are capable of depleting 100% of the serum lytic ability even in the absence of Ag, whereas IgG4mutp shows no evidence of activity in this assay under any of the conditions tested. Additionally, we show that, in contrast to monomeric IgG, polymeric IgGs bind with very high affinity to Fc gamma receptor II (Fc gamma RII), a low affinity receptor for wild-type antibodies; however, binding to Fc gamma Rl, the high affinity receptor, appears to be unaltered. Finally, the in vivo t1/2 of the gamma mutp proteins is decreased relative to wild-type IgG, apparently because of rapid clearance of the polymeric fraction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7868896

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  A peptide extension dictates IgM assembly.

Authors:  Dzana Pasalic; Benedikt Weber; Chiara Giannone; Tiziana Anelli; Roger Müller; Claudio Fagioli; Manuel Felkl; Christine John; Maria Francesca Mossuto; Christian F W Becker; Roberto Sitia; Johannes Buchner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-27       Impact factor: 11.205

2.  Influence of the mu-chain C-terminal sequence on polymerization of immunoglobulin M.

Authors:  A Getahun; M Lundqvist; D Middleton; G Warr; L Pilström
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

3.  rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.

Authors:  Rolf Spirig; Ian K Campbell; Sandra Koernig; Chao-Guang Chen; Bonnie J B Lewis; Rebecca Butcher; Ineke Muir; Shirley Taylor; Jenny Chia; David Leong; Jason Simmonds; Pierre Scotney; Peter Schmidt; Louis Fabri; Andreas Hofmann; Monika Jordi; Martin O Spycher; Susann Cattepoel; Jennifer Brasseit; Con Panousis; Tony Rowe; Donald R Branch; Adriana Baz Morelli; Fabian Käsermann; Adrian W Zuercher
Journal:  J Immunol       Date:  2018-03-12       Impact factor: 5.422

4.  Enhanced opsonisation of Rhesus D-positive human red blood cells by recombinant polymeric immunoglobulin G anti-G antibodies.

Authors:  Dylana Díaz-Solano; Jaheli Fuenmayor; Ramon F Montaño
Journal:  Blood Transfus       Date:  2017-05-30       Impact factor: 3.443

Review 5.  Sialylation as an Important Regulator of Antibody Function.

Authors:  Ravi Vattepu; Sunny Lyn Sneed; Robert M Anthony
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

6.  Role of Bordetella O antigen in respiratory tract infection.

Authors:  Valorie C Burns; Elizabeth J Pishko; Andrew Preston; Duncan J Maskell; Eric T Harvill
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  Polymeric human Fc-fusion proteins with modified effector functions.

Authors:  David N A Mekhaiel; Daniel M Czajkowsky; Jan Terje Andersen; Jianguo Shi; Marwa El-Faham; Michael Doenhoff; Richard S McIntosh; Inger Sandlie; Jianfeng He; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  Sci Rep       Date:  2011-10-19       Impact factor: 4.379

8.  A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

Authors:  Rob N de Jong; Frank J Beurskens; Sandra Verploegen; Kristin Strumane; Muriel D van Kampen; Marleen Voorhorst; Wendy Horstman; Patrick J Engelberts; Simone C Oostindie; Guanbo Wang; Albert J R Heck; Janine Schuurman; Paul W H I Parren
Journal:  PLoS Biol       Date:  2016-01-06       Impact factor: 8.029

9.  Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications.

Authors:  Daniel M Czajkowsky; Jan Terje Andersen; Anja Fuchs; Timothy J Wilson; David Mekhaiel; Marco Colonna; Jianfeng He; Zhifeng Shao; Daniel A Mitchell; Gang Wu; Anne Dell; Stuart Haslam; Katy A Lloyd; Shona C Moore; Inger Sandlie; Patricia A Blundell; Richard J Pleass
Journal:  Sci Rep       Date:  2015-04-27       Impact factor: 4.379

10.  Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions.

Authors:  O S Qureshi; T F Rowley; F Junker; S J Peters; S Crilly; J Compson; A Eddleston; H Björkelund; K Greenslade; M Parkinson; N L Davies; R Griffin; T L Pither; K Cain; L Christodoulou; L Staelens; E Ward; J Tibbitts; A Kiessling; B Smith; F R Brennan; M Malmqvist; F Fallah-Arani; D P Humphreys
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.